Laurent Décosterd

Publications | Mémoires et thèses

La recherche avancée est accessible via Serval

Les publications peuvent être gérées en accédant à Serval via MyUnil


325 publications

... | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 |
2009
Tamoxifen metabolism and the impact of Tamoxifen dose on the level of the active metabolites in endocrine sensitive breast cancer patients
Dahmane Elyes, Csajka Chantal, Decosterd Laurent, Mercier Thomas, Zanolari Boris, Eap Chin, Buclin Thierry, Galmiche Marie, Zaman Khalil, 2009/09. dans ''Frontiers in drug discovery and development'' : 24ème séminaire, 3ème cycle, en sciences pharmaceutiques.
[URN][serval:BIB_646DE6013BB6]
 
A LC-tandem MS assay for the simultaneous measurement of new antiretroviral agents: Raltegravir, maraviroc, darunavir, and etravirine.
Fayet A., Béguin A., Zanolari B., Cruchon S., Guignard N., Telenti A., Cavassini M., Günthard H.F., Buclin T., Biollaz J. et al., 2009. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences, 877 (11-12) pp. 1057-1069.
[DOI][WoS][Pmid][serval:BIB_C3A49D552F26]
A phase I pharmacokinetic study of hypoxic abdominal stop-flow perfusion with gemcitabine in patients with advanced pancreatic cancer and refractory malignant ascites
Kuemmerle A., Decosterd L. A., Buclin T., Liénard D., Stupp R., Chassot P. G., Mosimann F., Lejeune F., 2009. Cancer Chemotherapy and Pharmacology, 63 (2) pp. 331-341. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_BD2D72C44FA2]
 
A single LC-tandem mass spectrometry method for the simultaneous determination of 14 antimalarial drugs and their metabolites in human plasma.
Hodel Eva Maria, Zanolari Boris, Mercier Thomas, Biollaz Jérôme, Keiser J., Olliaro P., Genton B., Decosterd Lurent-Arthur, 2009. Journal of Chromatography. B, Analytical Technologies In the Biomedical and Life Sciences, 877 (10) pp. 867-886.
[DOI][WoS][Pmid][serval:BIB_1E04925415B7]
 
Drug uptake in a rodent sarcoma model after intravenous injection or isolated lung perfusion of free/liposomal doxorubicin.
Cheng C., Haouala A., Krueger T., Mithieux F., Perentes J.Y., Peters S., Decosterd L.A., Ris H.B., 2009. Interactive Cardiovascular and Thoracic Surgery, 8 (6) pp. 635-638.
[DOI][Pmid][serval:BIB_1E63104FAB1A]
 
Ganciclovir exposure under a 450 mg daily dosage of valganciclovir for cytomegalovirus prevention in kidney transplant recipients: a prospective study : P125
Manuel O., Pascual M., Perrottet N., Lamoth F., Venetz J.P., Decosterd L., Buclin T., Meylan P., 2009. pp. 32S-33S dans Joint Annual Congress of the Swiss Society for Allergology and Immunology and the Swiss Society for Infectious Diseases, Swiss Medical Weekly. Peer-reviewed.
[WoS][serval:BIB_80EADAB09A91]
 
Ganciclovir Exposure under a 450 mg Daily Dosage of Valganciclovir for the Prevention of Cytomegalovirus Disease in Kidney Transplant Recipients.
Manuel Oriol, Pascual Manuel, Perrottet Nancy, Lamoth Frederic, Venetz Jean-Pierre, Decosterd Laurent, Buclin Thierry, Meylan Pascal R., 2009. p. 249 dans 9th Joint Meeting of the American Society of Transplant Surgeon and of the American Society of Transplantation, American Journal of Transplantation. Peer-reviewed.
[WoS][serval:BIB_18DA47E61C5B]
 
In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function.
di Iulio J., Fayet A., Arab-Alameddine M., Rotger M., Lubomirov R., Cavassini M., Furrer H., Günthard H.F., Colombo S., Csajka C. et al., 2009. Pharmacogenetics and Genomics, 19 (4) pp. 300-309. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_69748BF486BC]
 
Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals.
Arab-Alameddine M., Di Iulio J., Buclin T., Rotger M., Lubomirov R., Cavassini M., Fayet A., Décosterd L.A., Eap C.B., Biollaz J. et al., 2009. Clinical Pharmacology and Therapeutics, 85 (5) pp. 485-494. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_09C3908EC60D]
Pharmacokinetic parameters of artesunate and dihydroartemisinin in rats infected with Fasciola hepatica
Keiser Jennifer, Gruyer Marie-Stella, Perrottet Nancy, Zanolari Boris, Mercier Thomas, Decosterd Laurent, 2009. Journal of Antimicrobial Chemotherapy, 63 (3) pp. 543-549. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_E0878357BDA9]
 
Population pharmacokinetics of ganciclovir in solid-organ transplant recipients receiving oral valganciclovir.
Perrottet N., Csajka C., Pascual M., Manuel O., Lamoth F., Meylan P., Aubert J.D., Venetz J.P., Soccal P., Decosterd L.A. et al., 2009. Antimicrobial agents and chemotherapy, 53 (7) pp. 3017-23.
[DOI][WoS][Pmid][serval:BIB_6BCA0E0A0A40]
 
Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry.
Haouala A., Zanolari B., Rochat B., Montemurro M., Zaman K., Duchosal M.A., Ris H.B., Leyvraz S., Widmer N., Decosterd L.A., 2009. Journal of Chromatography. B, 877 (22) pp. 1982-1996. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_2DB8EE377DD2]
 
Valganciclovir in adult solid organ transplant recipients: pharmacokinetic and pharmacodynamic characteristics and clinical interpretation of plasma concentration measurements.
Perrottet N., Decosterd L.A., Meylan P., Pascual M., Biollaz J., Buclin T., 2009. Clinical Pharmacokinetics, 48 (6) pp. 399-418. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_CB0583FDF1A4]
2008
 
Determination of unbound antiretroviral drug concentrations by a modified ultrafiltration method reveals high variability in the free fraction.
Fayet A., Béguin A., de Tejada B.M., Colombo S., Cavassini M., Gerber S., Eap C.B., Telenti A., Buclin T., Biollaz J. et al., 2008/08. Therapeutic drug monitoring, 30 (4) pp. 511-522. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_14181C037D30]
 
Imatinib metabolite profiling in parallel to imatinib quantification in plasma of treated patients using liquid chromatography-mass spectrometry.
Rochat B., Fayet A., Widmer N., Lahrichi S.L., Pesse B., Décosterd L.A., Biollaz J., 2008/02. Journal of mass spectrometry, 43 (6) pp. 736-52. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_9FBD3ADEE3DF]
 
Disposition of oral valganciclovir during continuous renal replacement therapy in two lung transplant recipients
Perrottet Nancy, Robatel Corinne, Meylan Pascal, Pascual Manuel, Venetz Jean-Pierre, Aubert John-David, Berger Mette M., Decosterd Laurent A., Biollaz Jerome, Buclin Thierry, 2008. p. 566 dans 8th American Transplant Congress, American Journal of Transplantation. Peer-reviewed.
[WoS][serval:BIB_90C644532B8E]
Disposition of valganciclovir during continuous renal replacement therapy in two lung transplant recipients.
Perrottet N., Robatel C., Meylan P., Pascual M., Venetz J.P., Aubert J.D., Berger M.M., Decosterd L.A., Buclin T., 2008. Journal of Antimicrobial Chemotherapy, 61 (6) pp. 1332-1335.
[URN][DOI][WoS][Pmid][serval:BIB_FB953C5B3D78]
 
Distribution of free and liposomal doxorubicin after isolated lung perfusion in a sarcoma model.
Yan H., Cheng C., Haouala A., Krueger T., Ballini J.P., Peters S., Decosterd L.A., Letovanec I., Ris H.B., Andrejevic-Blant S., 2008. Annals of Thoracic Surgery, 85 (4) pp. 1225-1232.
[DOI][WoS][Pmid][serval:BIB_C03EDB2C0612]
 
Efavirenz Dose Adjustment in HIV Patients with Impaired CYP2B6 Function
Csajka C., Cavassini M., Rotger M., Decosterd L. A., Furrer H., Calmy A., Fayet A., Arab-Alameddine M., Widmer N., di Iulio J. et al., 2008. Pharmacotherapy, 28 (9) pp. 215e-216e. Peer-reviewed.
[serval:BIB_B959BE3BFC81]
 
Imatinib metabolite profiling in parallel to imatinib quantification in plasma of treated patients using liquid chromatography-mass spectrometry
Rochat B., Fayet A., Widmer N., Lahrichi S.L., Pesse B., Décosterd L.A., Biollaz J., 2008. Journal of Mass Spectrometry, 43 (6) pp. 736-752.
[DOI][Pmid][serval:BIB_529B6ADB1956]
 
Low-dose valganciclovir is efficacious and safe for prophylaxis of cytomegalovirus infection in kidney transplantation
Perrottet Nancy, Manuel Oriol, Venetz Jean-Pierre, Lamoth Frederic, Decosterd Laurent A., Buclin Thierry, Biollaz Jerome, Meylan Pascal, Pascual Manuel, 2008. pp. 565-566 dans 8th American Transplant Congress, American Journal of Transplantation. Peer-reviewed.
[WoS][serval:BIB_BA42B5399BF1]
Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability
Widmer N., Decosterd L. A., Leyvraz S., Duchosal M. A., Rosselet A., Debiec-Rychter M., Csajka C., Biollaz J., Buclin T., 2008. British Journal of Cancer, 98 (10) pp. 1633-1640. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_5285F3FECE13]
 
Suivi thérapeutique des médicaments (I). Les principes [Principles of therapeutic drug monitoring]
Widmer N., Csajka C., Werner D., Grouzmann E., Decosterd L.A., Eap C.B., Biollaz J., Buclin T., 2008. Revue Médicale Suisse, 4 (165) pp. 1644-1668. Peer-reviewed.
[Pmid][serval:BIB_56FB6F49D00F]
 
Suivi thérapeutique des médicaments (II). La pratique clinique [Therapeutic drug monitoring: clinical practice].
Widmer N., Werner D., Grouzmann E., Eap C.B., Marchetti O., Fayet A., Csajka C., Decosterd L.A., Buclin T., 2008. Revue Médicale Suisse, 4 (165) pp. 1649-1660. Peer-reviewed.
[Pmid][serval:BIB_53F56A1C36B3]
2007
 
Partial deletion of CYP2B6 owing to unequal crossover with CYP2B7
Rotger M., Saumoy M., Zhang K., Flepp M., Sahli R., Decosterd L., Telenti A., 2007/10. Pharmacogenetics and Genomics, 17 (10) pp. 885-90.
[DOI][WoS][Pmid][serval:BIB_01BE917E653A]
 
Determination of aciclovir and ganciclovir in human plasma by liquid chromatography-spectrofluorimetric detection and stability studies in blood samples
Perrottet N., Beguin A., Meylan P., Pascual M., Manuel O., Buclin T., Biollaz J., Decosterd L. A., 2007/06. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences, 852 (1-2) pp. 420-9.
[DOI][WoS][Pmid][serval:BIB_531C59A30064]
 
The role of compartment penetration in PI-monotherapy: the Atazanavir-Ritonavir Monomaintenance (ATARITMO) Trial
Vernazza P., Daneel S., Schiffer V., Decosterd L., Fierz W., Klimkait T., Hoffmann M., Hirschel B., 2007/06. AIDS, 21 (10) pp. 1309-15.
[DOI][WoS][Pmid][serval:BIB_C3C6DEA5695B]
 
Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals
Rotger M., Tegude H., Colombo S., Cavassini M., Furrer H., Decosterd L., Blievernicht J., Saussele T., Gunthard H. F., Schwab M. et al., 2007/04. Clinical Pharmacology and Therapeutics, 81 (4) pp. 557-66.
[DOI][WoS][Pmid][serval:BIB_5FC59E1DB87D]
 
Clinical consequences of imatinib plasma concentrations variability in hemato-oncologic patients
Widmer N., Leyvraz S., Duchosal M.A., Rosselet A., Csajka C., Henry H., Debiec-Rychter M., Eap C.B., Biollaz J., Buclin T. et al., 2007. p. 481 dans 10th International Congress of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT), Therapeutic Drug Monitoring. Peer-reviewed.
[WoS][serval:BIB_6B840EC11A9C]
 
Does tenofovir influence efavirenz pharmacokinetics?
Rotger M., Colombo S., Furrer H., Decosterd L., Buclin T., Telenti A., 2007. Antiviral Therapy, 12 (1) pp. 115-8.
[WoS][Pmid][serval:BIB_A7D2AFCBBA6A]
 
Effect of dronedarone on renal function in healthy subjects.
Tschuppert Y., Buclin T., Rothuizen L.E., Decosterd L.A., Galleyrand J., Gaud C., Biollaz J., 2007. British Journal of Clinical Pharmacology, 64 (6) pp. 785-791. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_29365D442E7A]
 
Pharmacokinetic and pharmacodynamic assessement of valganciclovir in the prophylaxis and treatment of CMV disease in solid organ transplant patients
Manuel O., Perrottet N., Lamoth F., Venetz J.P., Decosterd L.A., Buclin T., Pascual M., Meylan P., 2007. pp. 9S dans Annual Conference Swiss Society for Paediatrics, Swiss Medical Weekly. Peer-reviewed.
[WoS][serval:BIB_28547DFCE2DB]
 
Relations entre les taux plasmatiques d'imatinib et ses effets cliniques
Widmer N., Decosterd L.A., Leyvraz S., Duchosal M.A., Rosselet A., Debiec-Rychter M., Csajka C., Biollaz J., Buclin T., 2007. dans 14es Journées Franco-Suisses de Pharmacie Hospitalière.
[serval:BIB_3A8230D7BEEB]
 
Relationships between imatinib plasma levels and efficacy
Widmer N., Decosterd L.A., Leyvraz S., Duchosal M.A., Rosselet A., Debiec-Rychter M., Csajka C., Biollaz J., Buclin T., 2007. pp. 80S dans 75. Jahresversammlung der Schweizerisches Gesellschaft für Innere Medizin, Swiss Medical Forum = Forum Médical Suisse. Peer-reviewed.
[serval:BIB_04D9A704BCA5]
 
Resistance reversal by RNAi silencing of MDR1 in CML cells associated with increase in imatinib intracellular levels.
Widmer N., Rumpold H., Untergasser G., Fayet A., Buclin T., Decosterd L.A., 2007. Leukemia, 21 (7) pp. 1561-2; author reply 1562-4. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_7945159811E3]
 
Simultaneous alteration of de novo and salvage pathway to the deoxynucleoside triphosphate pool by (E)-2'-deoxy-(fluoromethylene)cytidine (FMdC) and zidovudine (AZT) results in increased radiosensitivity in vitro
Coucke P. A., Cottin E., Decosterd L. A., 2007. Acta Oncologica, 46 (5) pp. 612-20.
[DOI][WoS][Pmid][serval:BIB_37CAB75FE72B]
 
Variability of voriconazole plasma levels measured by new high-performance liquid chromatography and bioassay methods.
Pascual A., Nieth V., Calandra T., Bille J., Bolay S., Decosterd L.A., Buclin T., Majcherczyk P.A., Sanglard D., Marchetti O., 2007. Antimicrobial Agents and Chemotherapy, 51 (1) pp. 137-143.
[DOI][WoS][Pmid][serval:BIB_62560DA1D073]
2006
 
Population pharmacokinetics of atazanavir in patients with human immunodeficiency virus infection
Colombo S., Buclin T., Cavassini M., Decosterd L. A., Telenti A., Biollaz J., Csajka C., 2006/11. Antimicrobial Agents and Chemotherapy, 50 (11) pp. 3801-8.
[DOI][WoS][Pmid][serval:BIB_B3F88281E351]
 
Are plasma levels valid surrogates for cellular concentrations of antiretroviral drugs in HIV-infected patients?
Colombo S., Telenti A., Buclin T., Furrer H., Lee B. L., Biollaz J., Decosterd L. A., 2006/06. Therapeutic Drug Monitoring, 28 (3) pp. 332-8.
[DOI][WoS][Pmid][serval:BIB_34514467D3D9]
 
Biological effects of a dietary omega-3 polyunsaturated fatty acids supplementation in cystic fibrosis patients: a randomized, crossover placebo-controlled trial.
Panchaud A., Sauty A., Kernen Y., Decosterd L.A., Buclin T., Boulat O., Hug C., Pilet M., Roulet M., 2006/06. Clinical Nutrition, 25 (3) pp. 418-427. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_E4584C2980DA]
 
Pharmacogenetics
Lee-Tauber Belle, Decosterd Laurent A., Korb Reinhold, Telenti Amalio, 2006/05/16. pp. 155-187 dans Pharmacogenetics in infectious diseases chap. 9, Ian P Hall, Munir Pirohamed.
[serval:BIB_433B26A29F8B]
 
Determination of the novel non-peptidic HIV-protease inhibitor tipranavir by HPLC-UV after solid-phase extraction.
Colombo S., Béguin A., Marzolini C., Telenti A., Biollaz J., Decosterd L.A., 2006/02. Journal of Chromatography. B, 832 (1) pp. 138-143. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_240D221E7E2F]
 
Antegrade versus retrograde isolated lung perfusion: doxorubicin uptake and distribution in a sarcoma model.
Krueger T., Kuemmerle A., Andrejevic-Blant S., Yan H., Pan Y., Ballini J.P., Klepetko W., Decosterd L.A., Stupp R., Ris H.B., 2006. Annals of Thoracic Surgery, 82 (6) pp. 2024-2030.
[DOI][WoS][Pmid][serval:BIB_2BEC657CCDDF]
 
Cytostatic lung perfusion results in heterogeneous spatial regional blood flow and drug distribution: evaluation of different cytostatic lung perfusion techniques in a porcine model.
Krueger T., Kuemmerle A., Kosinski M., Denys A., Magnusson L., Stupp R., Delaloye A.B., Klepetko W., Decosterd L., Ris H.B. et al., 2006. Journal of Thoracic and Cardiovascular Surgery, 132 (2) pp. 304-311.
[DOI][WoS][Pmid][serval:BIB_318CA3BEDD68]
 
Oral imatinib treatment reduces early fibrogenesis but does not prevent progression in the long term
Neef M., Ledermann M., Saegesser H., Schneider V., Widmer N., Decosterd L. A., Rochat B., Reichen J., 2006/01. Journal of Hepatology, 44 (1) pp. 167-75. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_FB0ED134A39B]
 
Orosomucoid (alpha1-acid glycoprotein) plasma concentration and genetic variants: effects on human immunodeficiency virus protease inhibitor clearance and cellular accumulation.
Colombo S., Buclin T., Décosterd L.A., Telenti A., Furrer H., Lee B.L., Biollaz J., Eap C.B. and , 2006. Clinical pharmacology and therapeutics, 80 (4) pp. 307-18. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_859F62D8CAD6]
 
Pharmacokinetic and pharmacodynamic evaluation of valganciclovir in solid organ transplant patients
Manuel O., Perrottet N., Venetz J.P., Decosterd L.A., Buclin T., Pascual M., Meylan P., 2006. pp. S19 dans 12th International Society for infectious Diseases, International Journal of Infectious Diseases. Peer-reviewed.
[WoS][serval:BIB_C405A5C4A4C2]
 
Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein
Widmer N., Decosterd L.A., Csajka C., Leyvraz S., Duchosal M.A., Rosselet A., Rochat B., Eap C.B., Henry H., Biollaz J. et al., 2006. British journal of clinical pharmacology, 62 (1) pp. 97-112. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_6058765DDE09]
 
Prospective determination of plasma imipenem concentrations in critically ill children.
Giannoni E., Moreillon P., Cotting J., Moessinger A., Bille J., Décosterd L., Zanetti G., Majcherczyk P., Bugnon D., 2006. Antimicrobial Agents and Chemotherapy, 50 (7) pp. 2563-2568.
[DOI][WoS][Pmid][serval:BIB_E2F1AB540BD5]
 
Relations entre la pharmacocinétique de population de l'imatinib et l'alpha-1-glycoproteine acide chez des patients hémato-oncologiques
Widmer N., Decosterd L.A., Csajka C., Leyvraz S., Duchosal M.A., Rosselet A., Rochat B., Eap C.B., Henry H., Biollaz J. et al., 2006. dans 13es Journées Franco-Suisses de Pharmacie Hospitalière.
[serval:BIB_54B5CDF331B9]
 
Relationship between imatinib population pharmacokinetics and alpha-1-acid glycoprotein
Widmer N., Decosterd L.A., Csajka C., Leyvraz S., Duchosal M.A., Rosselet A., Rochat B., Eap C.B., Henry H., Biollaz J. et al., 2006. pp. 71S dans 74e Assemblée annuelle de la Société Suisse de Médecine Interne (SSMI), Swiss Medical Forum = Forum Médical Suisse. Peer-reviewed.
[serval:BIB_5CB9DE6BA9E2]
 
Ritonavir-boosted atazanavir-lopinavir combination: a pharmacokinetic interaction study of total, unbound plasma and cellular exposures
Colombo S., Buclin T., Franc C., Guignard N., Khonkarly M., Tarr P. E., Rochat B., Biollaz J., Telenti A., Decosterd L. A. et al., 2006. Antiviral Therapy, 11 (1) pp. 53-62.
[WoS][Pmid][serval:BIB_B50E136DB0CD]
2005
 
Influence of ABCB1, ABCC1, ABCC2, and ABCG2 haplotypes on the cellular exposure of nelfinavir in vivo
Colombo S., Soranzo N., Rotger M., Sprenger R., Bleiber G., Furrer H., Buclin T., Goldstein D., Decosterd L., Telenti A., 2005/09. Pharmacogenetics and Genomics, 15 (9) pp. 599-608.
[DOI][WoS][Pmid][serval:BIB_B3A8434770B5]
 
A validated liquid chromatography-mass spectrometry method for the determination of leukotrienes B4 and B5 produced by stimulated human polymorphonuclear leukocytes
Panchaud A., Avois L., Roulet M., Pilet M., Hug C., Saugy M., Decosterd L. A., 2005/06. Analytical Biochemistry, 341 (1) pp. 58-68.
[DOI][WoS][Pmid][serval:BIB_D4BD57B87E02]
 
Intracellular measurements of anti-HIV drugs indinavir, amprenavir, saquinavir, ritonavir, nelfinavir, lopinavir, atazanavir, efavirenz and nevirapine in peripheral blood mononuclear cells by liquid chromatography coupled to tandem mass spectrometry
Colombo S., Beguin A., Telenti A., Biollaz J., Buclin T., Rochat B., Decosterd L. A., 2005/05. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences, 819 (2) pp. 259-76.
[DOI][WoS][Pmid][serval:BIB_6FC687BADC2D]
 
Dietary supplementation with omega-3 in cystic fibrosis patients
Panchaud A., Sauty A., Kernen Y., Decosterd L.A., Buclin T., Hug C., Pilet M., Roulet M., 2005. pp. S88 dans 28th European Cystic Fibrosis Conference, Journal of Cystic Fibrosis. Peer-reviewed.
[serval:BIB_685CFB9F9BDB]
 
Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients
Rotger M., Colombo S., Furrer H., Bleiber G., Buclin T., Lee B. L., Keiser O., Biollaz J., Decosterd L., Telenti A., 2005/01. Pharmacogenetics and Genomics, 15 (1) pp. 1-5.
[Pmid][serval:BIB_664B41A07499]
 
Pharmacologie et toxicologie: le suivi thérapeutique des médicaments - vers un pilotage précis des traitements
Buclin T., Decosterd L.A., 2005. Swiss Medical Forum = Forum Médical Suisse, 5 (51-52) pp. 1301-1303.
[serval:BIB_4A44967DC02A]
 
Population pharmacokinetics of imatinib in CML and GIST patients under long-term treatment
Widmer N., Decosterd L.A., Leyvraz S., Duchosal M.A., Csajka C., Biollaz J., Buclin T., 2005. pp. 116-117 dans 7th Congress of the European Association for Clinical Pharmacology and Therapeutics (EACPT), Basic and Clinical Pharmacology and Toxicology. Peer-reviewed.
[serval:BIB_3529293D5FE2]
 
Population pharmacokinetics of imatinib in CML and GIST patients under long-term treatment
Widmer N., Decosterd L.A., Leyvraz S., Duchosal M.A., Csajka C., Biollaz J., Buclin T., 2005. pp. 63S dans 73e Assemblée annuelle de la Société Suisse de Médecine Interne (SSMI), Swiss Medical Forum = Forum Médical Suisse. Peer-reviewed.
[serval:BIB_5746C1EDC479]
 
Severe pustular eruption associated with imatinib and voriconazole in a patient with chronic myeloid leukemia
Gambillara E., Laffitte E., Widmer N., Decosterd L. A., Duchosal M. A., Kovacsovics T., Panizzon R. G., 2005. Dermatology, 211 (4) pp. 363-365. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_A154D5A1FF1A]
Variations of CYP3A activity induced by antiretroviral treatment in HIV-1 infected patients.
Fellay J., Marzolini C., Decosterd L., Golay K.P., Baumann P., Buclin T., Telenti A., Eap C.B., 2005. European journal of clinical pharmacology, 60 (12) pp. 865-73. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_7E60EAA242E4]
2004
 
Determination of the new HIV-protease inhibitor atazanavir by liquid chromatography after solid-phase extraction
Colombo S., Guignard N., Marzolini C., Telenti A., Biollaz J., Decosterd L. A., 2004/10. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences, 810 (1) pp. 25-34.
[DOI][WoS][Pmid][serval:BIB_21D53DE5F776]
 
Population pharmacokinetics of indinavir in patients infected with human immunodeficiency virus
Csajka C., Marzolini C., Fattinger K., Decosterd L. A., Telenti A., Biollaz J., Buclin T., 2004/09. Antimicrobial Agents and Chemotherapy, 48 (9) pp. 3226-32.
[DOI][WoS][Pmid][serval:BIB_1C445DFD3180]
 
Positive interactive radiosensitisation in vitro with the combination of two nucleoside analogues, (E)-2'-deoxy-2'-(fluoromethylene) cytidine and iododeoxyuridine
Coucke P. A., Cottin E., Azria D., Martineau P., Adamer F., Decosterd L. A., Buchegger F., Do H. P., 2004/07. European Journal of Cancer, 40 (10) pp. 1572-1580.
[DOI][WoS][Pmid][serval:BIB_547E8A3B3537]
 
Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients
Ostermann S., Csajka C., Buclin T., Leyvraz S., Lejeune F., Decosterd L. A., Stupp R., 2004/06. Clinical Cancer Research, 10 (11) pp. 3728-36.
[DOI][WoS][Pmid][serval:BIB_3B2D8C83B78B]
 
Determination of imatinib (Gleevec) in human plasma by solid-phase extraction-liquid chromatography-ultraviolet absorbance detection
Widmer N., Beguin A., Rochat B., Buclin T., Kovacsovics T., Duchosal M. A., Leyvraz S., Rosselet A., Biollaz J., Decosterd L. A., 2004/04. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences, 803 (2) pp. 285-292. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_4AC0838E2602]
 
Dose-adjustment of imatinib based on plasma level measurement in a patient with CML
Heizmann M., Widmer N., Decosterd L.A., Oppliger E., Tobler A., 2004. pp. 32S dans 72e Assemblée annuelle de la Société Suisse de Médecine Interne (SSMI), Swiss Medical Forum = Forum Médical Suisse. Peer-reviewed.
[serval:BIB_F83E06C2CF73]
 
Dose-adjustment of imatinib based on plasma level measurement in a patient with CML
Heizmann M., Widmer N., Decosterd L.A., Oppliger E., Tobler A., 2004. pp. S39 dans 9th Congress of the European Hematology Association (EHA), Hematology Journal. Peer-reviewed.
[serval:BIB_FE19890651C2]
2003
 
Pharmacokinetics and dosage adaptation of meropenem during continuous venovenous hemodiafiltration in critically ill patients
Robatel C., Decosterd L. A., Biollaz J., Eckert P., Schaller M. D., Buclin T., 2003/12. Journal of Clinical Pharmacology, 43 (12) pp. 1329-40.
[DOI][WoS][Pmid][serval:BIB_FB70FDC0E665]
 
Functional consequence of MDR1 expression on imatinib intracellular concentrations
Widmer N., Colombo S., Buclin T., Decosterd L. A., 2003/08. Blood, 102 (3) p. 1142. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_BCDCDDB61B48]
 
Pharmacokinetics of satraplatin (JM216), an oral platinum (IV) complex under daily oral administration for 5 or 14 days
Vouillamoz-Lorenz S., Buclin T., Lejeune F., Bauer J., Leyvraz S., Decosterd L. A., 2003/06. Anticancer Research, 23 (3C) pp. 2757-65.
[WoS][Pmid][serval:BIB_00344D20AA08]
 
A validated assay for measuring doxorubicin in biological fluids and tissues in an isolated lung perfusion model: matrix effect and heparin interference strongly influence doxorubicin measurements.
Kümmerle A., Krueger T., Dusmet M., Vallet C., Pan Y., Ris H.B., Decosterd L.A., 2003. Journal of Pharmaceutical and Biomedical Analysis, 33 (3) pp. 475-494. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_6CD0A263C34E]
 
NAT2 and CYP1A2 phenotyping with caffeine: head-to-head comparison of AFMU vs. AAMU in the urine metabolite ratios
Nyeki A., Buclin T., Biollaz J., Decosterd L. A., 2003/01. British Journal of Clinical Pharmacology, 55 (1) pp. 62-7.
[DOI][WoS][Pmid][serval:BIB_0295C4681187]
 
Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection.
Csajka C., Marzolini C., Fattinger K., Décosterd L.A., Fellay J., Telenti A., Biollaz J., Buclin T., 2003. Clinical pharmacology and therapeutics, 73 (1) pp. 20-30. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_39A9FD8E09B3]
2002
 
Determination of lopinavir and nevirapine by high-performance liquid chromatography after solid-phase extraction: application for the assessment of their transplacental passage at delivery
Marzolini C., Beguin A., Telenti A., Schreyer A., Buclin T., Biollaz J., Decosterd L. A., 2002/07. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences, 774 (2) pp. 127-40.
[DOI][WoS][Pmid][serval:BIB_FE146774859E]
 
Determination of meropenem in plasma and filtrate-dialysate from patients under continuous veno-venous haemodiafiltration by SPE-LC.
Robatel C., Buclin T., Eckert P., Schaller M.D., Biollaz J., Decosterd L.A., 2002. Journal of pharmaceutical and biomedical analysis, 29 (1-2) pp. 17-33. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_C053F7A8E078]
 
Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study.
Fellay J., Marzolini C., Meaden E.R., Back D.J., Buclin T., Chave J.P., Decosterd L.A., Furrer H., Opravil M., Pantaleo G. et al., 2002. The Lancet, 359 (9300) pp. 30-36. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_15EF32DDF0CC]
 
Single-step extraction of fluconazole from plasma by ultra-filtration for the measurement of its free concentration by high performance liquid chromatography.
Majcherczyk P.A., Moreillon P., Decosterd L.A., Sanglard D., Bille J., Glauser M.P., Marchetti O., 2002. Journal of Pharmaceutical and Biomedical Analysis, 28 (3-4) pp. 645-651.
[DOI][WoS][Pmid][serval:BIB_B7BF67540321]
 
Transplacental passage of protease inhibitors at delivery.
Marzolini C., Rudin C., Decosterd L.A., Telenti A., Schreyer A., Biollaz J., Buclin T., 2002. AIDS, 16 (6) pp. 889-893. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_24752]
2001
Population pharmacokinetics of fluconazole given for secondary prevention of oropharyngeal candidiasis in HIV-positive patients.
Csajka C., Décosterd L.A., Buclin T., Pagani J.L., Fattinger K., Bille J., Biollaz J., 2001/12. European journal of clinical pharmacology, 57 (10) pp. 723-727. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_0E4686924252]
 
Nelfinavir plasma levels under twice-daily and three-times-daily regimens: high interpatient and low intrapatient variability
Marzolini C., Buclin T., Decosterd L. A., Biollaz J., Telenti A., 2001/08. Therapeutic Drug Monitoring, 23 (4) pp. 394-8.
[DOI][WoS][Pmid][serval:BIB_AFB4A7406A45]
 
Validation of an AAS method for the determination of platinum in biological fluids from patients receiving the oral platinum derivative JM216
Vouillamoz-Lorenz S., Bauer J., Lejeune F., Decosterd L. A., 2001/06. Journal of Pharmaceutical and Biomedical Analysis, 25 (3-4) pp. 465-75.
[DOI][WoS][Pmid][serval:BIB_676DEA016210]
 
Extractionless method for the simultaneous high-performance liquid chromatographic determination of urinary caffeine metabolites for N-acetyltransferase 2, cytochrome P450 1A2 and xanthine oxidase activity assessment
Nyeki A., Biollaz J., Kesselring U. W., Decosterd L. A., 2001/05. Journal of Chromatography. B, Biomedical Sciences and Applications, 755 (1-2) pp. 73-84.
[DOI][WoS][Pmid][serval:BIB_B4267263CA95]
 
Midazolam premedication reduces propofol dose requirements for multiple anesthetic endpoints
Wilder-Smith O. H., Ravussin P. A., Decosterd L. A., Despland P. A., Bissonnette B., 2001/05. Canadian Journal of Anaesthesia, 48 (5) pp. 439-45.
[DOI][WoS][Pmid][serval:BIB_947D8233356F]
 
Diet acids and alkalis influence calcium retention in bone.
Buclin T., Cosma M., Appenzeller M., Jacquet A.F., Décosterd L.A., Biollaz J., Burckhardt P., 2001. Osteoporosis International, 12 (6) pp. 493-499.
[DOI][WoS][Pmid][serval:BIB_10A4123B1EC8]
 
Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients.
Marzolini C., Telenti A., Decosterd L.A., Greub G., Biollaz J., Buclin T., 2001. AIDS, 15 (1) pp. 71-75. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_84CEAFA7373C]
 
Rôle du suivi thérapeutique des concentrations d'antirétroviraux dans la prise en charge des patients HIV
Marzolini C., Décosterd L. A., Buclin T., Telenti A., Biollaz J., 2001. Médecine et Hygiène, 59 (2369) pp. 2302-2305.
[serval:BIB_9C38267673ED]
 
Validation of an HPLC method for the determination of urinary and plasma levels of N1-methylnicotinamide, an endogenous marker of renal cationic transport and plasma flow
Musfeld C., Biollaz J., Belaz N., Kesselring U. W., Decosterd L. A., 2001/01. Journal of Pharmaceutical and Biomedical Analysis, 24 (3) pp. 391-404.
[DOI][WoS][Pmid][serval:BIB_E9E8BF14D2A3]
2000
 
Continuous infusion of ceftazidime with a portable pump is as effective as thrice-a-day bolus in cystic fibrosis children
Rappaz I., Decosterd L. A., Bille J., Pilet M., Belaz N., Roulet M., 2000/12. European Journal of Pediatrics, 159 (12) pp. 919-925.
[DOI][WoS][Pmid][serval:BIB_70F0482C4825]
 
Simultaneous determination of the HIV protease inhibitors indinavir, amprenavir, saquinavir, ritonavir, nelfinavir and the non-nucleoside reverse transcriptase inhibitor efavirenz by high-performance liquid chromatography after solid-phase extraction
Marzolini C., Telenti A., Buclin T., Biollaz J., Decosterd L. A., 2000/03. Journal of Chromatography. B, Biomedical Sciences and Applications, 740 (1) pp. 43-58.
[DOI][WoS][Pmid][serval:BIB_645EE36B1BB1]
 
Efavirenz decreases methadone blood concentrations.
Marzolini C., Troillet N., Telenti A., Baumann P., Decosterd L.A., Eap C.B., 2000. AIDS, 14 (9) pp. 1291-1292. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_3264B6C2D4B7]
1999
Midazolam premedication and thiopental induction of anaesthesia: interactions at multiple end-points
Wilder-Smith O. H., Ravussin P. A., Decosterd L. A., Despland P. A., Bissonnette B., 1999/10. British Journal of Anaesthesia, 83 (4) pp. 590-5.
[URN][DOI][WoS][Pmid][serval:BIB_82813762066F]
 
The ribonucleoside diphosphate reductase inhibitor (E)-2'-deoxy-(fluoromethylene)cytidine as a cytotoxic radiosensitizer in vitro
Coucke P. A., Decosterd L. A., Li Y. X., Cottin E., Chen X., Sun L. Q., Stern S., Paschoud N., Denekamp J., 1999/10. Cancer Research, 59 (20) pp. 5219-26.
[WoS][Pmid][serval:BIB_96FE26517659]
Sequential administration of temozolomide and fotemustine: depletion of O6-alkyl guanine-DNA transferase in blood lymphocytes and in tumours
Gander M., Leyvraz S., Decosterd L., Bonfanti M., Marzolini C., Shen F., Lienard D., Perey L., Colella G., Biollaz J. et al., 1999/07. Annals of Oncology, 10 (7) pp. 831-8.
[URN][DOI][WoS][Pmid][serval:BIB_6B773617CF43]
 
Trace lithium in mood disorders
Dafflon M., Decosterd L. A., Biollaz J., Preisig M., Dufour H., Buclin T., 1999/07. Journal of Affective Disorders, 54 (1-2) pp. 199-203. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_31FC4B97AC47]
 
Simultaneous determination of deoxyribonucleoside in the presence of ribonucleoside triphosphates in human carcinoma cells by high-performance liquid chromatography
Decosterd L. A., Cottin E., Chen X., Lejeune F., Mirimanoff R. O., Biollaz J., Coucke P. A., 1999/05. Analytical Biochemistry, 270 (1) pp. 59-68.
[DOI][WoS][Pmid][serval:BIB_03CA5EABEAA5]
 
Effects of a dual inhibitor of angiotensin converting enzyme and neutral endopeptidase, MDL 100,240, on endocrine and renal functions in healthy volunteers.
Rousso P., Buclin T., Nussberger J., Décosterd L.A., La Roche S.D., Brunner-Ferber F., Brunner H.R., Biollaz J., 1999. Journal of Hypertension, 17 (3) pp. 427-437. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_1FFA0AB179F1]
 
Les transporteurs membranaires de médicaments : une cible pharmacologique séduisante
Zaman K., Buclin T., Decosterd L. A., Biollaz J., 1999. Médecine et Hygiène, 57 (2251) pp. 801-808.
[serval:BIB_E4F15AFDCD9D]
 
Pharmacocinétique du meropénème chez des patients de soins intensifs sous hémodiafiltration veno-veineuse continue (CVVHDF)
Robatel C., Buclin T., Decosterd L. A., Biollaz J., Eckert P., Broccard A., Vogel G., Wauters J. P., Chio-lero R., Schaller M. D., 1999. Nephrologie, 20(5) p. 247.
[serval:BIB_BF68C2FDB76E]
1998
 
Determination of trace lithium in human erythrocytes by electrothermal atomic-absorption spectrometry with pyrocoated graphite tubes and integrated platform
Decosterd L. A., Buclin T., Dafflon M., Leeman C., Belaz N., Magnin J. L., Biollaz J., 1998/06. Journal of Pharmacy and Pharmacology, 50 (6) pp. 693-701.
[WoS][Pmid][serval:BIB_7ACF7C2583C6]
 
Estimation of glomerular filtration rate by sinistrin clearance using various approaches
Buclin T., Sechaud R., Bertschi A. P., Decosterd L. A., Belaz N., Appenzeller M., Burnier M., Biollaz J., 1998/03. Renal Failure, 20 (2) pp. 267-76.
[DOI][WoS][Pmid][serval:BIB_BE2A0C977A87]
 
Specific determination of PAH and its N-acetyl metabolite by HPLC increases the accuracy and precision of PAH clearance measurements
Decosterd L. A., Belaz N., Appenzeller M., Maghraoui A., Rousso P., Buclin T., Biollaz J., 1998/03. Renal Failure, 20 (2) pp. 311-7.
[DOI][WoS][Pmid][serval:BIB_2BBF025FC8EC]
 
Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: comparison of oral, intravenous, and hepatic intra-arterial administration.
Marzolini C., Decosterd L.A., Shen F., Gander M., Leyvraz S., Bauer J., Buclin T., Biollaz J., Lejeune F., 1998. Cancer Chemotherapy and Pharmacology, 42 (6) pp. 433-440.
[DOI][WoS][Pmid][serval:BIB_7BB2FAA8F76D]
 
Renal response to the angiotensin II receptor subtype 1 antagonist irbesartan versus enalapril in hypertensive patients.
Pechère-Bertschi A., Nussberger J., Decosterd L., Armagnac C., Sissmann J., Bouroudian M., Brunner H.R., Burnier M., 1998. Journal of hypertension, 16 (3) pp. 385-93. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_04C6DC549FBA]
1997
 
Sinistrin clearance for determination of glomerular filtration rate: a reappraisal of various approaches using a new analytical method
Buclin T., Pechere-Bertschi A., Sechaud R., Decosterd L. A., Munafo A., Burnier M., Biollaz J., 1997/08. Journal of Clinical Pharmacology, 37 (8) pp. 679-92.
[DOI][WoS][Pmid][serval:BIB_4EB67937BDCA]
 
Effects of MDL 100,240 on the glomerular filtration rate and renal tubular function in healthy volunteers under high and low sodium
Rousso P., Buclin T., Décosterd L., Nussberger J., Appenzeller M., Bélaz N., La Roche S., Brunner F., Brunner H. R., Biollaz J., 1997. Clinical Pharmacology and Therapeutics, 61 p. 206.
[serval:BIB_8563A490BE07]
 
High-performance liquid chromatography of the renal blood flow marker p-aminohippuric acid (PAH) and its metabolite N-acetyl PAH improves PAH clearance measurements.
Decosterd L.A., Karagiannis A., Roulet J.M., Bélaz N., Appenzeller M., Buclin T., Vogel P., Biollaz J., 1997. Journal of chromatography. B, Biomedical sciences and applications, 703 (1-2) pp. 25-36.
[DOI][WoS][Pmid][serval:BIB_FDA84FF15C25]
 
Spectrophotometric determination of methylene blue in biological fluids after ion-pair extraction and evidence of its adsorption on plastic polymers
Bélaz-David N., Decosterd L.A., Appenzeller M., Ruetsch Y.A., Chiolero R., Buclin T., Biollaz J., 1997. European Journal of Pharmaceutical Sciences, 5 (6) pp. 335-345.
[DOI][WoS][serval:BIB_415873D2BE6E]
1996
 
Determination of the polyfructosan sinistrin in biological fluids by HPLC with electrochemical detection
Sechaud R., Decosterd L. A., Pechere-Bertschi A., Biollaz J., Kesselring U. W., 1996/02. Journal of Pharmaceutical and Biomedical Analysis, 14 (4) pp. 483-90.
[DOI][WoS][Pmid][serval:BIB_95D69C8B2A75]
 
Determination of the polyfructosan sinistrin in biological fluids by HPLC with electrochemical detection.
Séchaud R., Décosterd L.A., Pechère-Bertschi A., Biollaz J., Kesselring U.W., 1996. Journal of Pharmaceutical and Biomedical Analysis, 14 (4) pp. 483-490.
[Pmid][serval:BIB_7B79872A67D4]
 
Determination of trace lithium in biological fluids using graphite furnace atomic absorption spectrophotometry: variability of urine matrices circumvented by cation exchange solid phase extraction.
Magnin J.L., Decosterd L.A., Centeno C., Burnier M., Diezi J., Biollaz J., 1996. Pharmaceutica acta Helvetiae, 71 (4) pp. 237-246. Peer-reviewed.
[Pmid][serval:BIB_1322CA2919AC]
1995
 
Determination of temozolomide in human plasma and urine by high-performance liquid chromatography after solid-phase extraction
Shen F., Decosterd L. A., Gander M., Leyvraz S., Biollax J., Lejeune F., 1995/05. Journal of Chromatography B, Biomedical Applications, 667 (2) pp. 291-300.
[DOI][WoS][Pmid][serval:BIB_9F07B0BF669F]
1994
 
Novel naphthoquinones from Conospermum incurvum
Dai J. R., Decosterd L. A., Gustafson K. R., Cardellina, J. H., 2nd , Gray G. N., Boyd M. R., 1994/11. Journal of Natural Products, 57 (11) pp. 1511-6.
[WoS][Pmid][serval:BIB_DB0FF15E695B]
 
The Differential Cytotoxicity of Cardenolides from Thevetia ahouia
Decosterd L., Gustafson K.R., Cardellina J.H., Cragg G.M., Boyd M.R., 1994. Phytotherapy Research, 8 (2) pp. 74-77.
[DOI][WoS][serval:BIB_2B5E1BD7A009]
1993
 
Bioactive Natural Products : Detection, Isolation and Structure Determination
Marston A., Decosterd L., Hostettmann K., 1993/09/29. pp. 221-240 dans Bioactive Natural Products : Detection, Isolation and Structure Determination, Steven M. Colegate, Russell J. Molyneux.
[serval:BIB_6C4E0A5DAA43]
 
HIV inhibitory natural products. 11. Structure, absolute stereochemistry, and synthesis of conocurvone, a potent, novel HIV-inhibitory naphthoquinone trimer from a Conospermum sp
Decosterd Laurent A., Parsons Ian C., Gustafson Kirk R., Cardellina II John H., McMahon James B., Cragg Gordon M., Murata Yoshiko, Pannell Lewis K., Steiner Jorge R., 1993/07/01. Journal of the american chemical society 115 pp. 6673–6679.
[DOI][WoS][serval:BIB_A621F069C908]
1991
 
A new phloroglucinol derivative from Hypericum calycinum with antifungal and in vitro antimalarial activity.
Decosterd L.A., Hoffmann E., Kyburz R., Bray D., Hostettmann K., 1991. Planta Medica, 57 (6) pp. 548-551.
[DOI][WoS][Pmid][serval:BIB_D6C028043EFE]
1990
 
Centrifugal Partition Chromatography: A Recently Developed Liquid-Liquid Technique for the Rapid Isolation of Natural Products
Marston A, Slacanin I, Decosterd LA, Hostettmann K, 1990/06. Planta Med , 6 (56) p. 498.
[DOI][serval:BIB_767E1E93D800]
1989
 
New Hyperforin Derivatives from Hypericum revolutum VAHL with Growth-Inhibitory Activity against a Human Colon Carcinoma Cell Line
Decosterd Laurent A., Stoeckli-Evans Helen, Chapuis Jean-Charles, Msonthi Jerome D., Sordat. Bernard, Hostettmann Kurt, 1989/05/03. Helvetica Chimica Acta, 72 pp. 464-471.
[DOI][serval:BIB_582051977742]
 
New Cell Growth-Inhibitory Cyclohexadienone Derivatives from Hypericum calycinum L.
Decosterd L.A., Stoecklievans H., Chapuis J.C., Sordat B., Hostettmann K., 1989. Helvetica Chimica Acta, 72 (8) pp. 1833-1845.
[DOI][WoS][serval:BIB_D327A5FB08AC]
1988
 
Isolation of New Cytotoxic Constituents from Hypericum revolution and Hypericum calycinum by Liquid-Liquid Chromatography
Decosterd L. A., Stoeckli-Evans H., Chapuis J. C., Msonthi J. D., Hostettmann K., 1988/12. Planta Medica, 54 (6) p. 560.
[DOI][Pmid][serval:BIB_6A85B377646A]
1987
 
Application of semi-preparative high-performance liquid chromatography to difficult natural product separations
Decosterd L. A., Dorsaz A. C., Hostettmann K., 1987/10. Journal of Chromatography, 406 pp. 367-73.
[DOI][WoS][Pmid][serval:BIB_678646CC43F9]
1986
 
A New Antifungal Chromene and a Related Di-chromene from Hypericum revolutum
Decosterd L., Stoeckli-Evans H., Msonthi J. D., Hostettmann K., 1986/10. Planta Medica, 52 (5) p. 429.
[WoS][Pmid][serval:BIB_E21B04941675]
Partagez:
Unicentre - CH-1015 Lausanne
Suisse
Tél. +41 21 692 11 11
Canton de Vaud
Swiss University